Compile Data Set for Download or QSAR
maximum 50k data
Found 42 with Last Name = 'cornwall' and Initial = 'p'
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238166(US10017502, Example 7 | US9394291, 7)
Affinity DataIC50:  9.5nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238166(US10017502, Example 7 | US9394291, 7)
Affinity DataIC50:  9.5nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  10nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404277(US10017502, Example 8b)
Affinity DataIC50:  10nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  13nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404271(US10017502, Example 6a)
Affinity DataIC50:  13nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238161(US10017502, Example 5a | US9394291, 5a)
Affinity DataIC50:  16nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238161(US10017502, Example 5a | US9394291, 5a)
Affinity DataIC50:  16nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  40nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  40nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  58nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  58nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  82nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  82nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404265(US10017502, Example 4a)
Affinity DataIC50:  130nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238159(US10017502, Example 4b | US9394291, 4a)
Affinity DataIC50:  130nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  180nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  180nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238152(US10017502, Example 2 | US9394291, 2 | US9394291, ...)
Affinity DataIC50:  230nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404258(US10017502, Example 2a)
Affinity DataIC50:  230nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404265(US10017502, Example 4a)
Affinity DataIC50:  240nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238159(US10017502, Example 4b | US9394291, 4a)
Affinity DataIC50:  240nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238155(US10017502, Example 3 | US9394291, 3 | US9394291, ...)
Affinity DataIC50:  270nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404263(2-{(3S or 3R)-7-Fluoro-4-[(3-oxo-3,4-dihydro-2H-1,...)
Affinity DataIC50:  270nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238155(US10017502, Example 3 | US9394291, 3 | US9394291, ...)
Affinity DataIC50:  480nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238155(US10017502, Example 3 | US9394291, 3 | US9394291, ...)
Affinity DataIC50:  480nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  740nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238158(US10017502, Example 4 | US9394291, 4)
Affinity DataIC50:  740nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  1.40E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  1.40E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238167(US10017502, Example 8 | US9394291, 8 | US9394291, ...)
Affinity DataIC50:  1.60E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404276(US10017502, Example 8a)
Affinity DataIC50:  1.60E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238152(US10017502, Example 2 | US9394291, 2 | US9394291, ...)
Affinity DataIC50:  1.80E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238152(US10017502, Example 2 | US9394291, 2 | US9394291, ...)
Affinity DataIC50:  1.80E+3nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238163(US10017502, Example 6 | US9394291, 6 | US9394291, ...)
Affinity DataIC50:  1.90E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404273(US10017502, Example 6b)
Affinity DataIC50:  1.90E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  2.90E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238151(US10017502, Example 1 | US9394291, 1)
Affinity DataIC50:  2.90E+3nMpH: 7.5Assay Description:Test A2: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238162(US10017502, Example 5b | US9394291, 5b)
Affinity DataIC50:  4.90E+3nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238162(US10017502, Example 5b | US9394291, 5b)
Affinity DataIC50:  4.90E+3nMpH: 7.5Assay Description:Test A1: Briefly, in Test A1 the assay was run in 384 well format in 10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA 20 mM NaMoO4, 0.1 mM DTT and 10% glycerol at...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM238159(US10017502, Example 4b | US9394291, 4a)
Affinity DataIC50:  3.75E+4nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
TargetMineralocorticoid receptor [729-984](Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM404262(2-{(3S or 3R)-7-Fluoro-4-[(3-oxo-3,4-dihydro-2H-1,...)
Affinity DataIC50:  3.75E+4nMAssay Description:Test A1 and A2: In order to identify binding to the human MR LBD a scintillation proximity assay (SPA) was adapted to the 384-well format. The MR-LBD...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent